about
FXR agonist INT-747 upregulates DDAH expression and enhances insulin sensitivity in high-salt fed Dahl ratsProton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General PopulationVascular progenitors from cord blood-derived induced pluripotent stem cells possess augmented capacity for regenerating ischemic retinal vasculatureRationale and design for PACE: patients with intermittent claudication injected with ALDH bright cells.Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt-beta-catenin and Wnt-RhoA-Rac1 pathways.Overexpression of dimethylarginine dimethylaminohydrolase protects against cerebral vascular effects of hyperhomocysteinemia.A matrix micropatterning platform for cell localization and stem cell fate determination.Multifunctional in vivo vascular imaging using near-infrared II fluorescenceConcurrent generation of functional smooth muscle and endothelial cells via a vascular progenitor.Near-infrared II fluorescence for imaging hindlimb vessel regeneration with dynamic tissue perfusion measurement.Capillary electrophoretic and micellar electrokinetic separations of asymmetric dimethyl-L-arginine and structurally related amino acids: quantitation in human plasma.Symmetric dimethylarginine (SDMA) as endogenous marker of renal function--a meta-analysis.Beta2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies.Murine model of hindlimb ischemia.nAChRs mediate human embryonic stem cell-derived endothelial cells: proliferation, apoptosis, and angiogenesisEmbryonic stem cell-derived endothelial cells engraft into the ischemic hindlimb and restore perfusion.Discovery of novel determinants of endothelial lineage using chimeric heterokaryons.Plasma homocysteine, dietary B vitamins, betaine, and choline and risk of peripheral artery disease.Phytoestrogens and cardiovascular health.Direct induction of haematoendothelial programs in human pluripotent stem cells by transcriptional regulators.Endothelial cells derived from human iPSCS increase capillary density and improve perfusion in a mouse model of peripheral arterial disease.Activation of innate immunity is required for efficient nuclear reprogramming.The combination of 9p21.3 genotype and biomarker profile improves a peripheral artery disease risk prediction model.Walking impairment questionnaire improves mortality risk prediction models in a high-risk cohort independent of peripheral arterial disease status.Flow, NO, and atherogenesisTransient delivery of modified mRNA encoding TERT rapidly extends telomeres in human cells.Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial.A novel and potent inhibitor of dimethylarginine dimethylaminohydrolase: a modulator of cardiovascular nitric oxide.Transdifferentiation of human fibroblasts to endothelial cells: role of innate immunity.Cholinergic activation of hematopoietic stem cells: role in tobacco-related disease?Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease.Self-reported history of childhood smoking is associated with an increased risk for peripheral arterial disease independent of lifetime smoking burden.Hypercholesterolemia impairs exercise capacity in mice.Cholinergic modulation of angiogenesis: role of the 7 nicotinic acetylcholine receptor.Cell-free production of transducible transcription factors for nuclear reprogramming.The emerging role of the thioredoxin system in angiogenesisAssessing endothelial vasodilator function with the Endo-PAT 2000.Topical mecamylamine for diabetic macular edemaLow lifetime recreational activity is a risk factor for peripheral arterial disease.Biomarkers of peripheral arterial disease.
P50
Q27329677-573C75A9-D437-441A-823F-800487B8617AQ28548045-14C142BA-5446-42E8-81D9-67EA205F0025Q28655924-0FB6A62A-F7C1-4DB8-A814-86D573916324Q30399678-0450E336-419F-483D-AEE2-A7F7DF3DD778Q30485381-4479A37E-90D6-4C2B-A3BD-1E1A37B23367Q30493459-57296EA6-2AD0-4745-A5E2-C2B8E16660BDQ30497058-9D7FB000-F4E4-4C69-827C-D3F0C72E7950Q30537465-86F2BF57-95AF-480D-BE7F-41E3C9112393Q30568774-CC7D11B8-B664-4E81-880E-35068AC69A86Q30582504-42A07508-AF93-45EC-8863-654019F8D24CQ31139539-8EA10D96-D30B-4C51-91C9-0C4EC0AB7285Q33246409-15966C87-5C5B-4CD3-BBB4-444FF0ED9A46Q33295304-AFA62EB1-1A6C-488A-99FA-15AE07C9D962Q33410763-D8F49564-3F37-4EB9-897F-1D31EEFE3745Q33503262-9BB1D0C1-A025-403B-83F7-8A0B143C51AEQ33532341-23D1DFF5-CF7A-4CBD-89C9-1D09A242FBB1Q33563457-3498A49E-2134-42B3-95ED-09EE8AFA259AQ33915599-53C767E9-57C7-4F09-BA72-9AE468019EA4Q33916551-2EB3915B-1FCF-444D-B4E7-D97D5DFD21FAQ33935685-82B5A8A6-52F9-494F-9208-ABF8E5089177Q33991356-EF24A652-AD63-4463-AF33-EDFE66053859Q34034126-12136809-1A08-45A3-852C-9D90224202DFQ34140830-98023EAA-002D-4F4C-BBFF-4CF3A94783E0Q34321203-27060D80-8B4A-4402-985C-28880996CFE2Q34327487-D487426A-2433-46EE-84A5-3D7F6A090380Q34459333-02DA7CF0-3BCC-48BC-8D66-2EDB7942EB6EQ34807168-6EA05993-3349-47AD-9154-17E6D806A73EQ35019853-5DC599C1-1A82-4CF5-A413-83BC5557C0CBQ35022859-A4EC065E-B2C3-4431-8C9C-A09F97FAC91CQ35033211-5ECBDD57-9CCB-44B9-AB49-0DE81EA6F0B2Q35090446-1308A34C-3235-461B-A43C-B7A292800262Q35099756-936744E2-F612-4C5D-B6F2-AF9B117FC180Q35117350-2D533998-E42B-4E1E-850B-E64CCA89CC7CQ35117369-72A48C0C-116D-4927-B315-02B446E4304EQ35123792-1F5186B2-30C0-4D53-AE70-2BE8AB1817C7Q35123800-34149EA1-1B25-4424-A611-6BB79966CD2BQ35126339-96010148-E6C0-4CFC-B4A8-45223A6B40A0Q35126358-31207D73-9C9F-4E0A-BA82-7CF678B63C7BQ35154228-EF115007-E960-49DF-A887-CF5AB38F743CQ35170187-1915DDFC-8EAE-43A7-96BB-DFB239D0C483
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
John P. Cooke
@ast
John P. Cooke
@en
John P. Cooke
@es
John P. Cooke
@nl
John P. Cooke
@sl
جون بي. كوك
@ar
type
label
John P. Cooke
@ast
John P. Cooke
@en
John P. Cooke
@es
John P. Cooke
@nl
John P. Cooke
@sl
جون بي. كوك
@ar
altLabel
John Cooke
@en
prefLabel
John P. Cooke
@ast
John P. Cooke
@en
John P. Cooke
@es
John P. Cooke
@nl
John P. Cooke
@sl
جون بي. كوك
@ar
P106
P1153
7202378672
P21
P31
P496
0000-0003-0033-9138